GMAB vs MASS: fair value comparison
Genmab A/S and 908 Devices Inc. · Updated 2026-10-19
MASS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, GMAB currently ranks higher by quality score.
| GMAB | MASS | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $37.00 | $11.26 |
| 12-month range | $23.85–$38.48 | $5.09–$12.80 |
| Rank by discount to fair value | #76 of 108 Healthcare | — |
| Rank by quality score | #91 of 301 Healthcare | #92 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GMAB fair value analysis · MASS fair value analysis